France· FR:63894243
RETROVIR 250 mg, gélule
A zidovudine product containing zidovudine, registered in France by VIIV HEALTHCARE (PAYS-BAS), on the national reimbursement list. The same ATC class is registered in 15 of our 19 countries.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
Where it is registered
Zidovudine is registered in 15 of 19 countries.
Countries holding a registration under ATC J05AF01 (zidovudine), each read from that country’s own register.
- This record: France, from Base de données publique des médicaments — BDPM (France)
- 8 of them publish a price we can compare per daily dose
Zidovudine · ATC J05AF01
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of zidovudine costs, country by country.
Normalised to the WHO defined daily dose (0.6 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Zidovudine · price per daily dose (0.6 g)
USD · FX 28 Sept 2026
- CH Switzerland$10.96
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- ZIDOVUDINE
- Manufacturer
- VIIV HEALTHCARE (PAYS-BAS)
- Country
- France (FR)
- ATC code
- J05AF01
- ATC class
- Zidovudine
- Defined daily dose
- 0.6 g, O
- Reimbursed
- Yes
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- cip133400933880453plaquette(s) PVC-Aluminium de 40 gélule(s)EUR 126.74
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
321 interactions on record for zidovudine.
Graded by severity as the source publishes them — 36 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Zidovudine · interactions on record
321 records
- 36 severe
- 220 moderate
- 9 minor
- 55 info
Most severe, free to view
- CladribineL01BB04severe
- BexaroteneL01XF03severe
- BexarotenL01XX25severe
- Amphotericin BA07AA07moderate
1 more interaction with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Zidovudine in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomRetrovir 250mg capsulesViiV Healthcare UK Ltd
- SwitzerlandRetrovir AZT 250 mg, KapselnViiV Healthcare GmbH
- CzechiaRETROVIRViiV Healthcare BV, Amersfoort
- SpainRETROVIR 250 mg CAPSULAS DURASLaboratorios Viiv Healthcare S.L.
- FinlandRetrovirViiV Healthcare BV
- PolandRetrovirViiV Healthcare BV
- BelgiumRetrovir 250 mgViiV Healthcare
- SwedenRetrovir 250 mg Kapsel, hårdViiV Healthcare BV
Authorised across Europe · EMA
The same active substance is authorised in 19 EEA countries. Names it is sold under:
- Austria · Retrovir
- Belgium · Retrovir, Retrovir I.V.
- Bulgaria · Ретровир
- Czechia · Retrovir
- Germany · Retrovir, Retrovir I.V.
- Denmark · Retrovir
- Estonia · Retrovir
- Spain · Retrovir, Zidovudina Accord
- Finland · Retrovir
- United Kingdom (Northern Ireland) · Retrovir, Retrovir Iv
- Greece · Retrovir
- Ireland · Retrovir
- Italy · Retrovir
- Luxembourg · Retrovir, Retrovir I.V.
- Netherlands · Retrovir, Retrovir Infuus
- Poland · Retrovir
- Portugal · Retrovir, Retrovir Iv
- Romania · Retrovir
- Sweden · Retrovir
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/a623a855-e230-4306-a1d9-45d86b6890cb GET /v1/drugs/a623a855-e230-4306-a1d9-45d86b6890cb?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "63894243",
"date_amm": "1987-03-13",
"type_amm": "Procédure de reconnaissance mutuelle",
"numero_ue": null,
"substance": "ZIDOVUDINE",
"atc_source": "fr_atc_restore_2026-09-06",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "gélule",
"voies_administration": "orale",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about zidovudine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.